NeuroImmunoModulation
Journal metrics
Annual Clarivate and SCImago indicators.
| Year | JCR | SJR | ||||
|---|---|---|---|---|---|---|
| IF | IF quartile | Rank (percentile) | SJR | SJR quartile | Rank (percentile) | |
| 2025 | 3.7 | Q2 | 62.5% | 0.801 | Q2 | 77.3% |
| 2024 | 2.4 | Q3 | 36.3% | 0.653 | Q3 | 71.3% |
| 2023 | 2.2 | Q3 | 28.2% | 0.600 | Q3 | 70.9% |
| 2022 | 2.4 | Q4 | 25.6% | 0.663 | Q3 | 75.1% |
| 2021 | 2.8 | Q4 | 31.0% | 0.548 | Q3 | 69.9% |
| 2020 | — | — | 0.635 | Q3 | 73.4% | |
| 2019 | — | — | 0.488 | Q3 | 66.8% | |
| 2018 | — | — | 0.530 | Q3 | 67.0% | |
Impact history
Annual SJR and Impact Factor trend.
SJRIF
Journal record
eISSN
1021-7401
ISSN
1423-0216
country
CHcoverage
1994-2002, 2004-2026